Market and Product Forecasts: Targeted Cancer Therapies 2011-21

2012-08-01
Published : Aug-2012

The targeted therapies class has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade the market will become more fragmented as new targeted therapies are developed for niche populations. In addition to this, recent pricing restrictions in the Eurozone will impact sales growth of targeted cancer therapies in the five major EU markets.

Features and benefits

  • Analysis of sales forecasts of 28 targeted cancer therapy brands over the period 2011-21 in the seven major pharmaceutical markets.
  • Includes an overview of the overall targeted therapies market as well as country specific and brand specific forecasts.
  • Analysis of the impact of generics and biosimilars on the marketed targeted cancer therapy brands over the forecast period 2011-21
  • Analysis of pharmacoeconomic constraints likely to affect sales growth in the seven major pharmaceutical markets.

Highlights

Datamonitor forecasts the currently marketed targeted cancer therapies to achieve collective sales of $37.2bn by 2014 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), growing at a compound annual growth rate (CAGR) of 7.36% from 2011 to 2014.

In 2011 the MAbs achieved sales of $16.3bn accounting for 54% of the sales of currently marketed targeted cancer therapies. The impact of generic competition on small molecule brands is expected to be greater than the impact of biosimilar competition on MAbs.

The US has the largest patient population and will remain the largest market over the forecast period of 2011–21. The aggressive uptake of generics in the US market, means the L1X4, L1X9, and L4A0 classes are expected to see a significantly higher decrease in branded sales over the forecast period compared to the MAbs.

Your key questions answered

  • Access Datamonitor’s company-reported sales based market forecasts for 28 targeted cancer therapies in the US, Japan and the five major EU markets.
  • Analyze the sales forecasts in each of the seven major markets and for each of the targeted cancer therapy brands across the forecast period 2011-21.
  • Report is accompanied by a PowerPoint presentation and Excel deliverable showing the transparent methodology and forecasting assumptions.

Get your copy of this report @ http://www.reportsnreports.com/reports/182232-market-and-product-forecasts-targeted-cancer-therapies-2011-21-eurozone-price-cuts-impact-targeted-cancer-therapies-market.html

Report Details: 

Published: July 2012
No. of Pages: 88

Price: Single User License: US$11400         Corporate User License:US$ 28500

 

Table of Contents

OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports

MARKET DEFINITION
Market definition for the targeted cancer therapies class
Targeted cancer therapies by ATC class
Targeted cancer therapies not included in this report
Forecast methodology and assumptions
Methodology flow
Patent expiries

MARKET OVERVIEW AND CONTEXT
Current and future market dynamics overview
US forecast
Japan forecast
Five major EU markets
France
Germany
Italy
Spain
UK

PRODUCT FORECASTS
Adcetris (brentuximab vedotin; Seattle Genetics/Takeda)
Forecast assumptions
Adcetris forecast 2011–21
Afinitor (everolimus; Novartis)
Forecast assumptions
Afinitor forecast 2011–21
Arzerra (ofatumumab; Genmab/GlaxoSmithKline)
Forecast assumptions
Arzerra forecast 2011–21
Avastin (bevacizumab; Roche/Chugai)
Forecast assumptions
Avastin forecast 2011–21
Caprelsa (vandetanib; AstraZeneca)
Forecast assumptions
Caprelsa forecast 2011–21
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
Forecast assumptions
Erbitux forecast 2011–21
Erivedge (vismodegib; Roche)
Forecast assumptions
Erivedge forecast 2011–21
Gleevec (imatinib; Novartis)
Forecast assumptions
Gleevec forecast 2011–21
Herceptin (trastuzumab; Roche/Chugai)
Forecast assumptions
Herceptin forecast 2011–21
Inlyta (axitinib; Pfizer)
Forecast assumptions
Inlyta forecast 2011–21
Iressa (gefitinib; AstraZeneca)
Forecast assumptions
Iressa forecast 2011–21
Nexavar (sorafenib; Bayer Schering/Onyx)
Forecast assumptions
Nexavar forecast 2011–21
Perjeta (pertuzumab; Roche)
Forecast assumptions
Perjeta forecast 2011–21
Revlimid (lenalidomide; Celgene)
Forecast assumptions
Revlimid forecast 2011–21
Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
Forecast assumptions
Rituxan forecast 2011–21
Sprycel (dasatinib; Bristol-Myers Squibb)
Forecast assumptions
Sprycel forecast 2011–21
Sutent (sunitinib; Pfizer)
Forecast assumptions
Sutent forecast 2011–21
Tarceva (erlotinib; OSI Pharmaceuticals/Roche)
Forecast assumptions
Tarceva forecast 2011–21
Tasigna (nilotinib; Novartis)
Forecast assumptions
Tasigna forecast 2011–21
Thalomid (thalidomide; Celgene)
Forecast assumptions
Thalomid forecast 2011–21
Torisel (temsirolimus; Pfizer)
Forecast assumptions
Torisel forecast 2011–21
Tykerb (lapatinib; GlaxoSmithKline)
Forecast assumptions
Tykerb forecast 2011–21
Vectibix (panitumumab; Amgen)
Forecast assumptions
Vectibix forecast 2011–21
Velcade (bortezomib; Takeda/Johnson & Johnson)
Forecast assumptions
Velcade forecast 2011–21
Votrient (pazopanib; GlaxoSmithKline)
Forecast assumptions
Votrient forecast 2011–21
Xalkori (crizotinib; Pfizer)
Forecast assumptions
Xalkori forecast 2011–21
Yervoy (ipilimumab; Bristol-Myers Squibb)
Forecast assumptions
Yervoy forecast 2011–21
Zelboraf (vemurafenib; Roche/Daiichi Sankyo)
Forecast assumptions
Zelboraf forecast 2011–21

BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Other

APPENDIX
Forecast methodology
Volume and value forecast methodology
Price assumptions

Contact: [email protected] for further details.

Filed in: Pharmaceutical
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy